The U.S. Food and Drug Administration granted fast track status for the development of AstraZeneca’s diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.
AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.
Novartis’ heart failure drug Entresto failed a clinical trial in a new use, the Swiss drugmaker said, calling into question billions of dollars in potential revenue and taking the shine off one of the company’s largest growth prospects.
In veteran drug salesman Paul Hudson, Sanofi’s 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.
Early detection of cardiovascular disease is becoming possible due to research from Giovanna Guidoboni, Marjorie Skubic and a team at the University of Missouri.
More U.S. adults are dying from heart failure today than a decade ago, and the sharpest rise in mortality is happening among middle-aged and younger adults, a new study suggests.
Asklepios BioPharmaceutical (AskBio) secured a $235 million investment from Vida Ventures and TPG Capital.
Pfizer Inc. announced that tafamidis received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the treatment of patients with transthyretin cardiomyopathy, which is a rare, fatal and underdiagnosed condition associated with progressive heart failure.
Seniors with type 2 diabetes or those with diabetic complications were less likely to be hospitalized for heart failure while taking a sodium-glucose co-transporter 2 (SGLT2) inhibitor compared to dipeptidyl peptidase-4 (DPP4) inhibitors, another new class of oral antidiabetic drug, according to a study released in Cardiovascular Diabetology and conducted by Anthem Inc. and HealthCore.
When it launched in February of 2015, Meerkat looked like it was going to be the hottest social application since Facebook. Two years later, Meerkat’s live-streaming platform is gone, taken down in the fall of 2016 after losing a battle for users with the similar (but Twitter-backed) platform Periscope. But although the players have changed, interest in live streaming has stuck around – and in some cases, grown quickly as users see the possibilities for it and existing social platforms begin adding it to their arsenal of features.